Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is listed as the manufacturer on 5 FDA drug label records covering 5 distinct active ingredients predominantly human prescription drug products.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is named as the labeler on 5 FDA drug label records. Its catalogue spans 5 distinct active ingredients, led by AFLIBERCEPT, ALIROCUMAB, CEMIPLIMAB-RWLC, GARETOSMAB-GRTS. Most of these labels are human prescription drug products. Labelling across this portfolio most often references: adult patients, locally advanced, cell carcinoma, inner ear, indicated reduce, cutaneous squamous, hedgehog pathway, lung cancer. Use the table below to identify a specific product, then open it for full indications, dosage and warnings as filed with the FDA.
Active ingredients in this portfolio
| Active ingredient | Products |
|---|---|
| AFLIBERCEPT | 1 |
| ALIROCUMAB | 1 |
| CEMIPLIMAB-RWLC | 1 |
| GARETOSMAB-GRTS | 1 |
| LUNSOTOGENE PARVEC-CWHA | 1 |
Dosage forms and routes
| Dosage form | Products | Route | Products |
|---|---|---|---|
| — | — | INTRAVENOUS | 2 |
| — | — | INTRACOCHLEAR | 1 |
| — | — | INTRAVITREAL | 1 |
| — | — | SUBCUTANEOUS | 1 |
| — | — | — | — |
| — | — | — | — |
FDA drug products from Regeneron Pharmaceuticals, Inc.
| Brand name | Generic | Type | Route |
|---|---|---|---|
| EYLEA | AFLIBERCEPT | HUMAN PRESCRIPTION DRUG | INTRAVITREAL |
| LIBTAYO | CEMIPLIMAB-RWLC | HUMAN PRESCRIPTION DRUG | INTRAVENOUS |
| OTARMENI | LUNSOTOGENE PARVEC-CWHA | HUMAN PRESCRIPTION DRUG | INTRACOCHLEAR |
| Pasatru | GARETOSMAB-GRTS | HUMAN PRESCRIPTION DRUG | INTRAVENOUS |
| Praluent | ALIROCUMAB | HUMAN PRESCRIPTION DRUG | SUBCUTANEOUS |
Frequently asked questions
How many FDA drug products does Regeneron Pharmaceuticals, Inc. make?
5 FDA drug label records name Regeneron Pharmaceuticals, Inc. as the manufacturer, covering 5 distinct active ingredients.
What active ingredients does Regeneron Pharmaceuticals, Inc. produce?
The most frequent active ingredients in this portfolio are AFLIBERCEPT, ALIROCUMAB, CEMIPLIMAB-RWLC, GARETOSMAB-GRTS, LUNSOTOGENE PARVEC-CWHA.
Are Regeneron Pharmaceuticals, Inc. products prescription or over-the-counter?
The largest share of this company’s labels are human prescription drug products; check each product page for its own marketing status.
Does this page list prices or where to buy?
No. This is a labelling reference built from FDA data. It does not sell, price or recommend any medicine.
Labelling data reproduced from FDA Structured Product Labelling for identification only. This site does not sell, price or recommend any medicine.